J. Smolen

Rheumatology · 2002–2022

A researcher in the Science corpus: 33 papers; trusts 11 researchers and is trusted by 1 researcher here, as inferred from the citation graph.

Subfields

• Rheumatology — 285 citations into it; #123 of 221 by trust here, #5 by citations
• Molecular Biology — 50 citations into it; #14,427 of 17,773 by trust here, #10,193 by citations
• Oncology — 47 citations into it; #1,201 of 1,698 by trust here, #993 by citations
• Genetics — 22 citations into it
• Orthopedics and Sports Medicine — 18 citations into it
• Endocrinology, Diabetes and Metabolism — 9 citations into it

Whom J. Smolen trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. Daniel Aletaha
2. K. Redlich
3. N. Nishimoto
4. E. Myasoedova
5. J. Landis
6. S. Teitelbaum

Who trusts J. Smolen overall

1. Daniel Aletaha
2. Yen-Ju Lin
3. B. K. Pedersen

Papers from J. Smolen's perspective

Ordered by how strongly the researchers J. Smolen trusts endorse each paper. Same corpus, a different order for every researcher.

1. New therapies for treatment of rheumatoid arthritis. (The Lancet)
2. Treating rheumatoid arthritis to target: recommendations of an international task force (Annals of the Rheumatic Diseases)
3. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled… (Annals of the Rheumatic Diseases)
4. The measurement of observer agreement for categorical data.
5. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. (New England Journal of Medicine)
6. Kremen proteins are Dickkopf receptors that regulate Wnt/β-catenin signalling (Nature)
7. Evolving concepts of rheumatoid arthritis (Nature)
8. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. (New England Journal of Medicine)
9. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. (Gastroenterology)
10. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. (Cell)

Their papers

• Autoantigen microarrays for multiplex characterization of autoantibody responses (2002) — 682 citations
• Dickkopf-1 is a master regulator of joint remodeling (2007) — 1,345 citations
• EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs (2010) — 4,103 citations
• Inflammatory bone loss: pathogenesis and therapeutic intervention (2012) — 790 citations
• EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update (2022) — 1,431 citations
• 2019 Update of the Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA–EDTA) recommendations for the management of lupus nephritis (2020) — 719 citations
• EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update (2020) — 807 citations
• EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update (2020) — 2,212 citations
• 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus (2019) — 1,638 citations
• 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus (2019) — 3,045 citations
• Rheumatoid arthritis (2018) — 1,770 citations
• Diagnosis and Management of Rheumatoid Arthritis: A Review (2018) — 1,988 citations
• Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force (2017) — 612 citations
• European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update (2015) — 893 citations
• Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force (2015) — 1,399 citations
• Treat-to-target in systemic lupus erythematosus: recommendations from an international task force (2014) — 688 citations
• Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA) (2013) — 814 citations
• EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis (2013) — 693 citations
• EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update (2013) — 1,725 citations
• Treating rheumatoid arthritis to target: recommendations of an international task force (2010) — 2,111 citations